Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized placebo-controlled dose-ranging trial of MK-3102 in type 2 diabetes mellitus
2010-022193-13Phase 2Completed
- Sponsor
- MSD
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by MSD. Primary endpoints: Change in HbA1c, Change in 2-hour post-meal glucose and 1 more. Started Sep 2010; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-022193-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022193-13.